Know Labs has published the results of a proof-of-principle study that demonstrated the accuracy of its proprietary Bio-RFID sensor in quantifying various analytes in vitro with a 100% accuracy rate.

The diagnostic technology developer has conducted the study, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” in collaboration with the Mayo Clinic, an American non-profit organisation.

US-based Know Labs said that the full study is currently in the peer-review publishing procedure.

The Bio-RFID technology platform leverages electromagnetic energy in the form of radio waves to capture molecular signatures non-invasively. The signatures can be then converted into physiologically meaningful information and insights.

The company said that the technology has accurately measured several analytes inside and outside the body. The first use of the sensor is aimed at non-invasive glucose monitoring.

Know Labs CEO and chairman Ron Erickson said: “This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market.

“To put this into real-world context: imagine being able to continuously and accurately measure different aspects of your health on a molecular level using a pocket-sized (or smaller) sensor instead of a finger prick or a CGM probe.”

The study, conducted at the Mayo Clinic in Rochester, Minnesota in March 2021, consists of five experiments to show the ability of the Know Labs’ Bio-RFID sensor.

The experiments were designed to non-invasively measure concentrations of solutions by using a randomised double-blind trial design, as proxies for biochemical solutions.

According to the company, the study tested solutions like water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water.

Know Labs said that the Bio-RFID sensor collected values at 7501 frequencies by sweeping across the 1500 Megahertz (MHz) – 3000 MHz range at 0.2 MHz intervals.

The technology detected concentrations as low as 2000 parts per million (ppm) with evidence suggesting the capability to identify much smaller concentration differences.

As per the company, these in vitro results support the use of the technology for further non-invasive, physiologic and medical monitoring.